New drug aims to shrink hard-to-treat tumors in early human tests
NCT ID NCT07459998
First seen Mar 12, 2026 · Last updated May 10, 2026 · Updated 5 times
Summary
This study tests an experimental drug, SKB103, in 277 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy. The goal is to see if the drug is safe and can shrink tumors. The study has three parts: finding the right dose, expanding the dose, and testing it in specific tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai East Hospital, Tongj.University
Shanghai, Shanghai Municipality, 200123, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.